Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT5B | P51692 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | PTGES | O14684 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | TAS2R14 | Q9NYV8 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 2/20 | 0.36 |
| ▸ | CTSB | P07858 | 2/20 | 0.36 |
| ▸ | CTSS | P25774 | 2/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1856320 | 0.91 | STAT5B (0.42) | STAT5BHSD11B1PTGESSMN1; SMN2PTGER2 | |
| SCHEMBL3635463 | 0.86 | STAT5B (0.44) | STAT5BHSD11B1PTGESKCNH2TAS2R14 | |
| SCHEMBL1857094 | 0.83 | F2 (0.40) | PTGESSMN1; SMN2LMNAPTGDR2KMT2A | |
| SCHEMBL1857439 | 0.83 | PTGDR2 (0.39) | HSD11B1SMN1; SMN2LMNAPTGDR2MEN1 | |
| SCHEMBL1857129 | 0.81 | STAT5B (0.46) | STAT5BHSD11B1PTGESSMN1; SMN2KCNH2 | |
| SCHEMBL1857446 | 0.80 | PTGER2 (0.35) | HSD11B1PTGESSMN1; SMN2PTGER2TAS2R14 | |
| SCHEMBL28588131 | 0.76 | TAS2R14 (0.55) | STAT5BHSD11B1PTGESPTGER2KCNH2 | |
| SCHEMBL3724224 | 0.76 | CA12 (0.43) | STAT5BHSD11B1TAS2R14MEN1KMT2A | |
| SCHEMBL12550326 | 0.76 | STAT5B (0.52) | STAT5BHSD11B1PTGESKCNH2TAS2R14 | |
| SCHEMBL1864812 | 0.75 | PTGER1 (0.37) | ALDH1A1LMNAPTGDR2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105544-A1 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2011-05-05 | — | — | US | disclosed |
| WO-2009080722-A2 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105544-A1 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | AKR1C3, TPD52L2, HCCS | STAT5B 4233/4885HSD11B1 826/4885PTGES 3899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.